Results 1 to 10 of about 382,334 (303)

Interleukin-6 Inhibitor-Induced Leukocytoclastic Vasculitis: A Case Report With a Literature Review [PDF]

Case Reports in Immunology
Background Leukocytoclastic vasculitis (LCV) is a known hypersensitivity reaction to biologic agents, often linked to tumor necrosis factor‐α (TNF‐α)inhibitors. We present a rare case of LCV in a patient receiving tocilizumab, a monoclonal antibody directed against interleukin‐6 (IL‐6)receptor.
Tatevik Aloyan, Dinara Salimova, Ebrahim Mohamed, Hina Wazir   +3 more
doaj   +4 more sources

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)

Научно-практическая ревматология, 2023
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA).
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov   +16 more
doaj   +2 more sources

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?

Atherosclerosis Plus, 2023
Background and aims: Lipoprotein(a) [Lp(a)] and interleuking-6 (IL-6), an inflammation biomarker, have been established as distinct targets of the residual atherosclerotic cardiovascular disease (ASCVD) risk.
Anastasios Makris, Fotios Barkas, Petros P. Sfikakis, Evangelos Liberopoulos, Theodosios D. Filippatos, Kausik K. Ray, Aris P. Agouridis   +6 more
doaj   +5 more sources

Interleukin-6 inhibitor : tocilizumab

, 2016
Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6.
Mahler, Stephen M., Pile, Kevin (R17082), Stephen M. Mahler, Garry G. Graham, Kevin D. Pile, Graham, Garry G.   +5 more
core   +6 more sources

Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case series [PDF]

Frontiers in Medicine
ObjectiveTo describe the experience of using olokizumab (OKZ) in patients with polymyalgia rheumatica (PMR) who have contraindications or an inadequate response to methotrexate and require steroid-sparing therapy, and to analyze treatment outcomes in ...
Alexey D. Meshkov, Alexey L. Maslyanskiy, Anton L. Chudinov, Elena P. Ilivanova, Ilya O. Smitienko, Pavel I. Novikov, Anna V. Torgashina, Evgeniy V. Arseniev, Natalia O. Khovasova, Anton V. Naumov, Olga N. Tkacheva, Evgeny G. Zotkin   +11 more
doaj   +2 more sources

Interleukin-1β promotes interleulin-6 expression via ERK1/2 signaling pathway in canine dermal fibroblasts.

PLoS ONE, 2019
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in the regulation of the immune response and inflammation. In this study, we investigated effect of the proinflammatory cytokine interleukin-1β (IL-1β) on IL-6 expression in canine dermal ...
Nanako Kitanaka, Rei Nakano, Kanae Sugiura, Taku Kitanaka, Shinichi Namba, Tadayoshi Konno, Tomohiro Nakayama, Hiroshi Sugiya   +7 more
doaj   +2 more sources

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis

Медицинский совет, 2019
Despite progress in pharmacotherapy, there still are urgent needs in the development of new methods of drug therapy of rheumatoid arthritis (RA). New prospects for drug therapy are currently associated with sarilumab (SAR), recently registered in the ...
D. E. Karateev, E. L. Luchikhina
doaj   +3 more sources

Giant Cell Arteritis Refractory to Interleukin‐6 and Interleukin‐17 Inhibition Treated With Upadacitinib

ACR Open Rheumatology
Giant cell arteritis (GCA) is a granulomatous vasculitis that can involve both cranial and extracranial vessels. Although interleukin‐6 (IL‐6) receptor blockade is an established therapy, treatment options for medically refractory disease remain limited.
Luke S. Vest, Anam Ahmad, Sanhitha Valasareddy, Nancy Phillips, Adam Kilian   +4 more
doaj   +2 more sources

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Современная ревматология
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods.
P. A. Shesternya, A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Yu. Yu. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, A. A. Blinova, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, N. V. Yudina, E. N. Alekseev, E. L. Nasonov, A. M. Lila   +17 more
doaj   +2 more sources

In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor [PDF]

Bioscience, Biotechnology, and Biochemistry, 2021
ABSTRACT Interleukin-6 (IL-6) binds to the IL-6 receptor (IL-6R) subunit, related to autoimmune diseases and cytokine storm in COVID-19. In this study, we performed systematic evolution of ligands by exponential enrichment and identified a novel RNA aptamer. This RNA aptamer not only bound to IL-6R with a dissociation constant of 200 n m,
Ando, Takehiro, Yamamoto, Mizuki, Takamori, Yukio, Tsukamoto, Keita, Fuji, Daisuke, Kawakami, Takashi   +5 more
openaire   +2 more sources